Pao, William

Publications

Sort by

Co-Author Network

Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. 2025 GET IT
Elucidating the Cell Surfaceome to Accelerate Cancer Drug Development. Cancer discovery. 2024 Academic Article GET IT
Times cited: 9
The NIH-led research response to COVID-19. Science (New York, N.Y.). 2023 Academic Article GET IT
Times cited: 37
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of medicinal chemistry. 2022 Academic Article GET IT
Times cited: 24
Paradigms for the development of transformative medicines-lessons from the EGFR story. Annals of oncology : official journal of the European Society for Medical Oncology. 2022 Editorial Article GET IT
Times cited: 3
Catalyzing the field of precision oncology, one basket at a time. Nature medicine. 2018 Academic Article GET IT
Times cited: 3
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. Cancer discovery. 2018 Review GET IT
Times cited: 71